Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1987 1
1989 1
1996 1
1999 1
2000 3
2001 4
2002 1
2003 1
2005 2
2006 1
2007 2
2008 1
2009 2
2010 1
2011 1
2012 2
2014 2
2015 3
2016 10
2017 14
2018 15
2019 16
2020 14
2021 24
2022 35
2023 35
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Results by year

Filters applied: . Clear all
Page 1
ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery.
Righi E, Mutters NT, Guirao X, Del Toro MD, Eckmann C, Friedrich AW, Giannella M, Kluytmans J, Presterl E, Christaki E, Cross ELA, Visentin A, Sganga G, Tsioutis C, Tacconelli E. Righi E, et al. Among authors: visentin a. Clin Microbiol Infect. 2023 Apr;29(4):463-479. doi: 10.1016/j.cmi.2022.12.012. Epub 2022 Dec 22. Clin Microbiol Infect. 2023. PMID: 36566836
Deconstructing virus condensation.
Lopez N, Camporeale G, Salgueiro M, Borkosky SS, Visentín A, Peralta-Martinez R, Loureiro ME, de Prat-Gay G. Lopez N, et al. Among authors: visentin a. PLoS Pathog. 2021 Oct 14;17(10):e1009926. doi: 10.1371/journal.ppat.1009926. eCollection 2021 Oct. PLoS Pathog. 2021. PMID: 34648608 Free PMC article. Review.
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksma AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, Ghia P, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K; ERIC, the European Research Initiative on CLL. Baliakas P, et al. Among authors: visentin a. Blood. 2019 Mar 14;133(11):1205-1216. doi: 10.1182/blood-2018-09-873083. Epub 2019 Jan 2. Blood. 2019. PMID: 30602617 Free PMC article.
Peripheral nervous system involvement in lymphomas.
Briani C, Visentin A, Campagnolo M, Salvalaggio A, Ferrari S, Cavallaro T, Manara R, Gasparotti R, Piazza F. Briani C, et al. Among authors: visentin a. J Peripher Nerv Syst. 2019 Mar;24(1):5-18. doi: 10.1111/jns.12295. Epub 2019 Jan 8. J Peripher Nerv Syst. 2019. PMID: 30556258 Review.
Peripheral neuropathy as clinical onset of monoclonal IgM/k-related amyloidosis.
Briani C, Ferrari S, Berno T, Visentin A, Cacciavillani M, Cavallaro T, Fedrigo M, Rizzo S, Salvalaggio A, Trentin L, Piazza F. Briani C, et al. Among authors: visentin a. J Peripher Nerv Syst. 2023 Jun;28(2):262-265. doi: 10.1111/jns.12540. Epub 2023 Mar 10. J Peripher Nerv Syst. 2023. PMID: 36859783
Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
Castellani F, Visentin A, Schirinzi E, Salvalaggio A, Cacciavillani M, Candiotto C, Baratè C, Cellini A, Bertorelle R, Siciliano G, Trentin L, Briani C. Castellani F, et al. Among authors: visentin a. Neurol Neuroimmunol Neuroinflamm. 2023 May 3;10(4):e200122. doi: 10.1212/NXI.0000000000200122. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37137530 Free PMC article.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Among authors: visentin a. Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116. Haematologica. 2023. PMID: 36632738 Free PMC article. Clinical Trial.
180 results